$SLS
SELLAS Life Sciences Group, Inc.

2020 Q4 Form 10-Q Financial Statement

#000139047820000037 Filed on November 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $1.900M $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $3.290M $2.125M $2.385M
YoY Change 37.08% -10.9% 77.85%
% of Gross Profit
Research & Development $2.770M $2.367M $1.799M
YoY Change 23.11% 31.57% 4.59%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.060M $4.492M $4.184M
YoY Change 30.32% 7.36% 36.69%
Operating Profit -$4.492M
YoY Change
Interest Expense $0.00 $0.00 $60.00K
YoY Change -100.0% -100.0% -185.71%
% of Operating Profit
Other Income/Expense, Net $430.0K $20.00K -$4.202M
YoY Change -960.0% -100.48% 1348.97%
Pretax Income -$3.730M -$4.470M -$4.200M
YoY Change -50.27% 6.43% 1348.28%
Income Tax -$20.00K $0.00
% Of Pretax Income
Net Earnings -$3.720M -$4.473M -$4.202M
YoY Change -49.87% 6.45% 1348.97%
Net Earnings / Revenue -195.79%
Basic Earnings Per Share -$0.53
Diluted Earnings Per Share -$358.4K -$0.53 -$981.3K
COMMON SHARES
Basic Shares Outstanding 9.462M shares 8.418M shares 226.5M shares
Diluted Shares Outstanding 8.418M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.30M $8.200M $9.100M
YoY Change 383.56% -9.89% -9.0%
Cash & Equivalents $35.30M $8.200M $9.119M
Short-Term Investments
Other Short-Term Assets $500.0K $1.100M $1.100M
YoY Change -28.57% 0.0% -15.38%
Inventory
Prepaid Expenses
Receivables $1.100M
Other Receivables $0.00
Total Short-Term Assets $36.93M $9.333M $10.21M
YoY Change 348.01% -8.6% -42.66%
LONG-TERM ASSETS
Property, Plant & Equipment $900.0K $900.0K $300.0K
YoY Change 350.0% 200.0%
Goodwill $1.914M $1.914M $1.914M
YoY Change 0.74% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $700.0K $600.0K
YoY Change 20.0% 16.67% -45.45%
Total Long-Term Assets $9.124M $9.176M $11.27M
YoY Change 9.05% -18.6% -45.44%
TOTAL ASSETS
Total Short-Term Assets $36.93M $9.333M $10.21M
Total Long-Term Assets $9.124M $9.176M $11.27M
Total Assets $46.05M $18.51M $21.48M
YoY Change 177.25% -13.85% -44.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.657M $1.779M $3.764M
YoY Change 19.35% -52.74% -48.0%
Accrued Expenses $1.913M $2.304M $1.504M
YoY Change 63.36% 53.19% -67.88%
Deferred Revenue $5.600M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.34M $4.219M $5.574M
YoY Change 133.19% -24.31% -53.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.500M $6.100M $4.900M
YoY Change 10.0% 24.49% -22.22%
Total Long-Term Liabilities $5.500M $6.100M $4.900M
YoY Change 10.0% 24.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.34M $4.219M $5.574M
Total Long-Term Liabilities $5.500M $6.100M $4.900M
Total Liabilities $18.09M $10.56M $10.85M
YoY Change 72.0% -2.64% -45.8%
SHAREHOLDERS EQUITY
Retained Earnings -$117.9M -$114.2M -$93.73M
YoY Change 16.57% 21.84% 36.77%
Common Stock $145.9M $122.1M $104.4M
YoY Change 36.02% 17.03% 19.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.96M $7.948M $10.64M
YoY Change
Total Liabilities & Shareholders Equity $46.05M $18.51M $21.48M
YoY Change 177.25% -13.85% -44.15%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$3.720M -$4.473M -$4.202M
YoY Change -49.87% 6.45% 1348.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $3.420M -$3.630M -$3.820M
YoY Change -182.01% -4.97% -73.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.67M 8.490M 190.0K
YoY Change 920.26% 4368.42% -98.67%
NET CHANGE
Cash From Operating Activities 3.420M -3.630M -3.820M
Cash From Investing Activities
Cash From Financing Activities 23.67M 8.490M 190.0K
Net Change In Cash 27.09M 4.860M -3.630M
YoY Change -1564.32% -233.88% -4637.5%
FREE CASH FLOW
Cash From Operating Activities $3.420M -$3.630M -$3.820M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001390478
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33958
dei Entity File Number
EntityFileNumber
001-33958
dei Entity Registrant Name
EntityRegistrantName
SELLAS Life Sciences Group, Inc.
dei Entity Registrant Name
EntityRegistrantName
SELLAS Life Sciences Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8099512
dei Entity Address Address Line1
EntityAddressAddressLine1
7 Times Square, Suite 2503,
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
(917)
dei Local Phone Number
LocalPhoneNumber
438-4353
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SLS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9461978 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8203000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7277000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 USD
CY2020Q3 gale Stock Subscription Receivable Current
StockSubscriptionReceivableCurrent
0 USD
CY2019Q4 gale Stock Subscription Receivable Current
StockSubscriptionReceivableCurrent
308000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
557000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
9333000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
8242000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
911000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
217000 USD
CY2020Q3 gale In Process Research Development
InProcessResearchDevelopment
5700000 USD
CY2019Q4 gale In Process Research Development
InProcessResearchDevelopment
5700000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
1914000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
262000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
1914000 USD
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
651000 USD
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
536000 USD
CY2020Q3 us-gaap Assets
Assets
18509000 USD
CY2019Q4 us-gaap Assets
Assets
16609000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1779000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3902000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2304000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1171000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
136000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
217000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4219000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5290000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
873000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
262000 USD
CY2020Q3 gale Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
5180000 USD
CY2020Q3 gale Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
27000 USD
CY2019Q4 gale Fair Value Of Warrants Potentially Settleable In Cash
FairValueOfWarrantsPotentiallySettleableInCash
52000 USD
CY2019Q4 gale Contingent Purchase Price Consideration Net Of Current Portion
ContingentPurchasePriceConsiderationNetOfCurrentPortion
4912000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
10561000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
10516000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114188000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
7948000 USD
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9461978 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9461978 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5080100 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5080100 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
10000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
122126000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
107235000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101147000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6093000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18509000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16609000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2367000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1799000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6511000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5039000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2125000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2385000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6312000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7523000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
4492000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
4184000 USD
us-gaap Costs And Expenses
CostsAndExpenses
12823000 USD
us-gaap Costs And Expenses
CostsAndExpenses
12562000 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6000 USD
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
49000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-25000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1108000 USD
CY2020Q3 gale Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
13000 USD
CY2019Q3 gale Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-28000 USD
gale Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-268000 USD
gale Change In Fair Value Of Contingent Purchase Price Consideration
ChangeInFairValueOfContingentPurchasePriceConsideration
-510000 USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 USD
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
59000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
25000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
91000 USD
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
19000 USD
CY2019Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-18000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-218000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
689000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4473000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4202000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13041000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11873000 USD
CY2020Q3 gale Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
0 USD
CY2019Q3 gale Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
7268000 USD
gale Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
78000 USD
gale Dividend Arising From Warrant Modifications
DividendArisingFromWarrantModifications
8659000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4473000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11470000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13119000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20532000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.37
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8418038 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4281855 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7174859 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1805773 shares
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3783000 USD
CY2020Q3 gale Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
8492000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4473000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7948000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6093000 USD
gale Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
14455000 USD
gale Stock Issued During Period Value Pre Funded Warrant
StockIssuedDuringPeriodValuePreFundedWarrant
4000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
437000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-13041000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7948000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14338000 USD
CY2019Q3 gale Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
383000 USD
CY2019Q3 gale Stock Issued During Period Value Pre Funded Warrant
StockIssuedDuringPeriodValuePreFundedWarrant
3000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
115000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4202000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10637000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5245000 USD
gale Stock Issued During Period Value Common Stockand Warrants
StockIssuedDuringPeriodValueCommonStockandWarrants
13416000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3658000 USD
gale Stock Issued During Period Value Pre Funded Warrant
StockIssuedDuringPeriodValuePreFundedWarrant
8000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426000 USD
gale Dividend Modification Of Warrants
DividendModificationOfWarrants
243000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11873000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10637000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13041000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-11873000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
437000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
426000 USD
gale Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
98000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1133000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-715000 USD
gale Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
0 USD
gale Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
25000 USD
gale Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
1108000 USD
gale Change In Fair Value Of Contingent Purchase Consideration
ChangeInFairValueOfContingentPurchaseConsideration
-268000 USD
gale Change In Fair Value Of Contingent Purchase Consideration
ChangeInFairValueOfContingentPurchaseConsideration
-510000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
588000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
480000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2123000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-227000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13841000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13467000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14455000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13652000 USD
gale Proceeds From Stock Subscription Receivable
ProceedsFromStockSubscriptionReceivable
308000 USD
gale Proceeds From Stock Subscription Receivable
ProceedsFromStockSubscriptionReceivable
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3598000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14767000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17250000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
926000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3783000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7377000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5451000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8303000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9234000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
25000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
87000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
976000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
550000 USD
gale Increase Decrease In Fair Value Of Warrant Liability
IncreaseDecreaseInFairValueOfWarrantLiability
0 USD
gale Increase Decrease In Fair Value Of Warrant Liability
IncreaseDecreaseInFairValueOfWarrantLiability
243000 USD
gale Noncash Offering Expense
NoncashOfferingExpense
0 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
4200000 USD
CY2020Q3 gale Contract Research Payable
ContractResearchPayable
1202000 USD
gale Noncash Offering Expense
NoncashOfferingExpense
236000 USD
gale Reclassification Of Warrant Liability Upon Exercise
ReclassificationOfWarrantLiabilityUponExercise
0 USD
gale Reclassification Of Warrant Liability Upon Exercise
ReclassificationOfWarrantLiabilityUponExercise
68000 USD
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
818900 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8200000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
100000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114200000 USD
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
227800147 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4549208 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4242000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
325000 shares
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
693000 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
200000 USD
CY2020Q3 gale Prepaid Research And Development
PrepaidResearchAndDevelopment
181000 USD
CY2019Q4 gale Prepaid Research And Development
PrepaidResearchAndDevelopment
224000 USD
CY2020Q3 gale Prepaid Professional Services
PrepaidProfessionalServices
125000 USD
CY2019Q4 gale Prepaid Professional Services
PrepaidProfessionalServices
49000 USD
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31000 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
84000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
557000 USD
CY2019Q4 gale Contract Research Payable
ContractResearchPayable
371000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
719000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
606000 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
383000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2304000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1171000 USD
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 USD
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
75000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
302000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
311000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
321000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
330000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1339000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
330000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1009000 USD
CY2020Q3 gale Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
100000 USD
CY2019Q3 gale Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
100000 USD
gale Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
300000 USD
gale Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
300000 USD
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
524097 shares
CY2019 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
2700000 USD
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0 shares
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
818900 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3864000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
208000 shares
CY2020Q3 gale Options Reserved For Future Issuance Under Companies Incentive Plan
OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan
101000 shares
CY2020Q3 gale Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan
CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan
8000 shares
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4351000 shares
CY2019 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
75000 shares
CY2019 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
300000 USD
CY2020Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
300000 USD
CY2019Q4 gale Stock Subscription Receivable Current
StockSubscriptionReceivableCurrent
300000 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
302000 shares
gale Class Of Warrant Or Right Number Of Warrants Issued
ClassOfWarrantOrRightNumberOfWarrantsIssued
4012000 shares
gale Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
449000 shares
gale Classof Warrantor Right Canceled Or Expired
ClassofWarrantorRightCanceledOrExpired
1000 shares
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3864000 shares
CY2019Q4 gale Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
52000 USD
gale Fair Valueof Warrants Granted
FairValueofWarrantsGranted
0 USD
gale Fair Value Of Warrants Canceled
FairValueOfWarrantsCanceled
0 USD
gale Fair Value Of Warrants Exercise Price Adjustment
FairValueOfWarrantsExercisePriceAdjustment
0 USD
gale Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
25000 USD
CY2020Q3 gale Fair Value Of Warrants Liabilities
FairValueOfWarrantsLiabilities
27000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
115000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
437000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
426000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0062
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0249
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0624
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9657
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21520 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
112.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
54.00
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
800000 USD
gale Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition
EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition
P2Y1M13D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M23D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
186000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.87
gale Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue
0 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
207520 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M29D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
145000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10892 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
129.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M28D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 USD
CY2020Q3 gale Closing Price Of Common Stock
ClosingPriceOfCommonStock
2.65

Files In Submission

Name View Source Status
0001390478-20-000037-index-headers.html Edgar Link pending
0001390478-20-000037-index.html Edgar Link pending
0001390478-20-000037.txt Edgar Link pending
0001390478-20-000037-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gale-20200930.htm Edgar Link pending
gale-20200930.xsd Edgar Link pending
gale-20200930_cal.xml Edgar Link unprocessable
gale-20200930_def.xml Edgar Link unprocessable
gale-20200930_g1.jpg Edgar Link pending
gale-20200930_htm.xml Edgar Link completed
gale-20200930_lab.xml Edgar Link unprocessable
gale-20200930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sls20200930ex103.htm Edgar Link pending
sls20200930ex311.htm Edgar Link pending
sls20200930ex312.htm Edgar Link pending
sls20200930ex321.htm Edgar Link pending